Moderna eyes mRNA cancer vaccine expansion beyond melanoma, kidney trial next

Moderna expresses confidence that its mRNA cancer vaccine will be effective in more cancer types beyond melanoma, with a large kidney cancer trial potentially among the next to report. This signals pipeline expansion but remains early-stage; efficacy in kidney cancer is unproven. The statement is forward-looking and not yet backed by clinical data.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works